Fact CheckerSign in

NCT05876078Completed

DORAYA-HF OUS Assessment of the Doraya Catheter for the Treatment of ADHF Patients With Insufficient Response to Diuretics

DORAYA-HF EU: Assessment of the Doraya Catheter for the Treatment of Volume Overload in Acute Heart Failure Patients With Insufficient Response to Diuretics

Source: ClinicalTrials.gov · Last updated 9 Mar 2026

Brief summary (registry, in English)

The study objective is to evaluate the feasibility of the Doraya Catheter and measure clinical performance and safety endpoints, in ADHF patients deemed to have insufficient diuretic response.

Status (registry)
Completed
Study type
Interventional
Enrollment
25 (actual)
First submitted
16 May 2023
Start date
1 Jul 2024
Primary completion date
28 Feb 2026
Lead sponsor
Revamp Medical Ltd.
NCT number
NCT05876078

What you commit to

  • Study type: Interventional
  • Participants enrolled: 25
  • From 1 Jul 2024 to the primary completion date, 28 Feb 2026
  • 10 sites in 5 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Systolic blood pressure \< 80 mmHg at the time of screening. 2. Acute myocardial infarction or acute coronary syndrome or cardiogenic shock or pleurocentesis within past 14 days or cardiovascular intervention within past 14 days. 3. Complex congenital heart disease (e.g., Tetralogy of Fallot subjects, single ventricle physiology).
  • 4\. Known active myocarditis, hypertrophic obstructive cardiomyopathy, infiltrative cardiomyopathy (e.g., amyloidosis), constrictive pericarditis or cardiac tamponade.
  • 5\. Severe Aortic valvular disorder (i.e., hemodynamically relevant valvular diseases such as severe stenosis \\severe regurgitation) or Severe mitral disease with planned intervention.
  • 6\. Evidence of active systemic infection documented by either one of the following: fever \>38°C/100°F, or ongoing uncontrolled infection (i.e., inflammatory parameters not decreasing despite \> 48 hours of antibiotic treatment).

Other

  • 7\. Moribund subject or subject with severe or deteriorating damage in more than 3 critical body systems, based on investigator's clinical judgement.

Who the study is looking for

  • Subject is hospitalized with primary diagnosis of ADHF.
  • N-terminal-pro-brain natriuretic peptide (NT-proBNP) ≥1,000 pg/m orvBNP≥250 pg/mL.
  • Evidence of fluid overload.
  • Subject insufficiently responds to IV diuretic therapy

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (10)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Heartcenter Dresden
Coordinator of this site? Confirm its status
DresdenGermanyUnknown status
Klinikum Fürth
Coordinator of this site? Confirm its status
FürthGermanyUnknown status
UKSH Universitäres Herzzentrum Lübeck
Coordinator of this site? Confirm its status
LübeckGermanyUnknown status
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Coordinator of this site? Confirm its status
MainzGermanyUnknown status
Hospital Clinic de Barcelona
Coordinator of this site? Confirm its status
BarcelonaSpainUnknown status
Hospital Clinico Universitario de Valencia
Coordinator of this site? Confirm its status
ValenciaSpainUnknown status
A.O.U Pisana Cisanello
Coordinator of this site? Confirm its status
PisaItalyUnknown status
Mikulicz-Radecki University Teaching Hospital in Wrocław
Coordinator of this site? Confirm its status
WroclawPolandUnknown status
SÚSCCH
Coordinator of this site? Confirm its status
Banská BystricaSlovakiaUnknown status
CINRE s.r.o.
Coordinator of this site? Confirm its status
BratislavaSlovakiaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.